Back to news

BioLargo Reports Third Quarter 2026 Results, Forecasting Commercial Breakout in 2027

ACCESSWIRE•17/11/2026•08:30 ET
0

Key Highlights

  • ➤Q3 revenue $1.09 million, down 1% year over year
  • ➤Nine-month revenue $3.452 million, down 52% year over year
  • ➤Nine-month net loss $11.229 million, up 2% year over year
  • ➤Clyra Medical funded $4.299 million, primarily through debt
  • ➤BioLargo launched barebird consumer odor products in October 2026

Expert Statements

Dennis P. Calvert, CEO of BioLargo, Inc.

“We've focused our energies on investing to ensure 2027 is a breakout year for BioLargo, with new medical product lines and selling channels, a new consumer product line just launched under our brand name ‘barebird’, and we continue developing and expanding important commercial relationships in the water and energy industries.”

Dennis P. Calvert, CEO of BioLargo, Inc.

“We built the channels, the supply chain and partnerships, and most of this work was funded inside the subsidiaries rather than the parent. That is why we expect in 2027 to shift our spending away from R&D and toward generating sales, as we move from developing products to selling them.”

Tonya Chandler, President of BioLargo Equipment Solutions & Technologies, Inc.

“Attention has historically focused on federal drinking-water rulemaking, and that market is very much alive. Lawsuit settlements in the billions of dollars are expected to fund PFAS treatment at public water systems, much of it for projects not yet underway, and we're well positioned to compete for that work.”

Tonya Chandler, President of BioLargo Equipment Solutions & Technologies, Inc.

“But drinking water was never the whole market. The requirements aren't receding. Based on our observations, they're spreading to wastewater, landfill leachate, biosolids, industrial pre-treatment and shorter-chain compounds. Industry is also paying attention to more than regulation. These billion-dollar settlements address harm to communities and public health, and any operator with PFAS in its waste stream can see that exposure. Increasingly, they're choosing to treat at the source now, regardless of when federal enforcement arrives.”

Dennis P. Calvert, President and CEO of BioLargo, Inc.

“In every market we serve - PFAS removal, grid-scale energy storage, infection control and wound care, industrial and household odor control - customers have lived with the drawbacks of the incumbent technologies because there hasn't been a better option.”

Dennis P. Calvert, President and CEO of BioLargo, Inc.

“Our products and solutions are designed to be that option - for our customers and for the partners who sell them.”

WESTMINSTER, CA / ACCESS Newswire / November 17, 2026 / BioLargo, Inc. (OTCQX:BLGO), a cleantech and life sciences company, today reported financial results for the third quarter ended September 30, 2026, and provided an update on commercialization activities across its portfolio of companies. The company filed its Quarterly Report on Form 10-Q on November 16, 2026 (www.BioLargo.com/SEC-filings). The company will forego a quarterly earnings call, as its Annual Meeting of Stockholders will be held on December 1, 2026, in Aliso Viejo, California.

Net losses reflect continued investment in commercialization, led by Clyra Medical which accounted for $6.4 million (57%) of the nine-month net loss, as it invested in personnel, manufacturing, product development and clinical activities to support its distributors and prepare for the national rollout of an additional product line expected in 2027. Clyra financed this work largely through debt, which also increased interest expense.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in